vs
Side-by-side financial comparison of Adaptive Biotechnologies Corp (ADPT) and Community West Bancshares (CWBC). Click either name above to swap in a different company.
Adaptive Biotechnologies Corp is the larger business by last-quarter revenue ($71.7M vs $38.3M, roughly 1.9× Community West Bancshares). On growth, Adaptive Biotechnologies Corp posted the faster year-over-year revenue change (51.0% vs 11.6%). Community West Bancshares produced more free cash flow last quarter ($43.6M vs $1.4M). Over the past eight quarters, Community West Bancshares's revenue compounded faster (36.0% CAGR vs 30.8%).
ExpreS2ion Biotechnologies is a Danish biotechnology company specialised in the development of new vaccines and immunotherapy products based in Hørsholm, Denmark and listed on the Nasdaq First North Growth Market Sweden.
Community West BancsharesCWBCEarnings & Financial Report
Community West Bancshares is a registered bank holding company headquartered in California. It wholly owns Community West Bank under the Bank Holding Company Act.
ADPT vs CWBC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $71.7M | $38.3M |
| Net Profit | $-13.6M | — |
| Gross Margin | 74.6% | — |
| Operating Margin | -17.8% | 40.0% |
| Net Margin | -18.9% | — |
| Revenue YoY | 51.0% | 11.6% |
| Net Profit YoY | 59.7% | — |
| EPS (diluted) | $-0.08 | $0.58 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $71.7M | $38.3M | ||
| Q3 25 | $94.0M | $37.9M | ||
| Q2 25 | $58.9M | $35.7M | ||
| Q1 25 | $52.4M | $34.8M | ||
| Q4 24 | $47.5M | $34.3M | ||
| Q3 24 | $46.4M | $31.3M | ||
| Q2 24 | $43.2M | $30.5M | ||
| Q1 24 | $41.9M | $20.7M |
| Q4 25 | $-13.6M | — | ||
| Q3 25 | $9.5M | $10.9M | ||
| Q2 25 | $-25.6M | $7.8M | ||
| Q1 25 | $-29.9M | $8.3M | ||
| Q4 24 | $-33.7M | — | ||
| Q3 24 | $-32.1M | $3.4M | ||
| Q2 24 | $-46.2M | $-6.3M | ||
| Q1 24 | $-47.5M | $3.7M |
| Q4 25 | 74.6% | — | ||
| Q3 25 | 80.7% | — | ||
| Q2 25 | 69.4% | — | ||
| Q1 25 | 67.6% | — | ||
| Q4 24 | 62.0% | — | ||
| Q3 24 | 64.1% | — | ||
| Q2 24 | 55.3% | — | ||
| Q1 24 | 56.9% | — |
| Q4 25 | -17.8% | 40.0% | ||
| Q3 25 | 10.9% | 39.8% | ||
| Q2 25 | -42.5% | 30.2% | ||
| Q1 25 | -56.4% | 32.7% | ||
| Q4 24 | -71.3% | 31.0% | ||
| Q3 24 | -70.3% | 13.3% | ||
| Q2 24 | -109.6% | -25.9% | ||
| Q1 24 | -116.5% | 23.2% |
| Q4 25 | -18.9% | — | ||
| Q3 25 | 10.2% | 28.7% | ||
| Q2 25 | -43.5% | 22.0% | ||
| Q1 25 | -56.9% | 23.8% | ||
| Q4 24 | -71.0% | — | ||
| Q3 24 | -69.1% | 10.8% | ||
| Q2 24 | -107.0% | -20.7% | ||
| Q1 24 | -113.5% | 17.8% |
| Q4 25 | $-0.08 | $0.58 | ||
| Q3 25 | $0.06 | $0.57 | ||
| Q2 25 | $-0.17 | $0.41 | ||
| Q1 25 | $-0.20 | $0.44 | ||
| Q4 24 | $-0.22 | $0.29 | ||
| Q3 24 | $-0.22 | $0.18 | ||
| Q2 24 | $-0.31 | $-0.33 | ||
| Q1 24 | $-0.33 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $70.5M | $119.0M |
| Total DebtLower is stronger | — | $69.5M |
| Stockholders' EquityBook value | $218.8M | $409.6M |
| Total Assets | $512.7M | $3.7B |
| Debt / EquityLower = less leverage | — | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $70.5M | $119.0M | ||
| Q3 25 | $55.0M | $121.6M | ||
| Q2 25 | $43.2M | $134.4M | ||
| Q1 25 | $50.6M | $148.4M | ||
| Q4 24 | $47.9M | $120.4M | ||
| Q3 24 | $38.1M | $149.0M | ||
| Q2 24 | $59.8M | $109.7M | ||
| Q1 24 | $71.2M | $61.0M |
| Q4 25 | — | $69.5M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $69.9M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $218.8M | $409.6M | ||
| Q3 25 | $204.4M | $397.6M | ||
| Q2 25 | $179.7M | $380.0M | ||
| Q1 25 | $190.4M | $372.2M | ||
| Q4 24 | $202.7M | $362.7M | ||
| Q3 24 | $223.8M | $363.5M | ||
| Q2 24 | $241.6M | $350.2M | ||
| Q1 24 | $274.9M | $211.7M |
| Q4 25 | $512.7M | $3.7B | ||
| Q3 25 | $490.6M | $3.6B | ||
| Q2 25 | $496.6M | $3.6B | ||
| Q1 25 | $510.9M | $3.6B | ||
| Q4 24 | $539.4M | $3.5B | ||
| Q3 24 | $558.5M | $3.5B | ||
| Q2 24 | $584.9M | $3.5B | ||
| Q1 24 | $620.3M | $2.4B |
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.19× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.1M | $46.1M |
| Free Cash FlowOCF − Capex | $1.4M | $43.6M |
| FCF MarginFCF / Revenue | 2.0% | 113.9% |
| Capex IntensityCapex / Revenue | 0.9% | 6.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-48.9M | $77.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.1M | $46.1M | ||
| Q3 25 | $-7.1M | $13.2M | ||
| Q2 25 | $-12.4M | $11.5M | ||
| Q1 25 | $-28.5M | $11.1M | ||
| Q4 24 | $-12.5M | $22.2M | ||
| Q3 24 | $-27.1M | $7.8M | ||
| Q2 24 | $-17.3M | $5.2M | ||
| Q1 24 | $-38.4M | $4.0M |
| Q4 25 | $1.4M | $43.6M | ||
| Q3 25 | $-7.5M | $12.8M | ||
| Q2 25 | $-13.1M | $10.6M | ||
| Q1 25 | $-29.7M | $10.8M | ||
| Q4 24 | $-12.6M | $17.2M | ||
| Q3 24 | $-27.4M | $5.2M | ||
| Q2 24 | $-19.0M | $4.8M | ||
| Q1 24 | $-39.9M | $3.6M |
| Q4 25 | 2.0% | 113.9% | ||
| Q3 25 | -8.0% | 33.7% | ||
| Q2 25 | -22.2% | 29.6% | ||
| Q1 25 | -56.7% | 30.9% | ||
| Q4 24 | -26.5% | 50.0% | ||
| Q3 24 | -59.0% | 16.7% | ||
| Q2 24 | -44.1% | 15.7% | ||
| Q1 24 | -95.2% | 17.3% |
| Q4 25 | 0.9% | 6.6% | ||
| Q3 25 | 0.4% | 1.1% | ||
| Q2 25 | 1.1% | 2.7% | ||
| Q1 25 | 2.4% | 0.9% | ||
| Q4 24 | 0.2% | 14.7% | ||
| Q3 24 | 0.7% | 8.1% | ||
| Q2 24 | 4.0% | 1.4% | ||
| Q1 24 | 3.6% | 2.1% |
| Q4 25 | — | — | ||
| Q3 25 | -0.75× | 1.21× | ||
| Q2 25 | — | 1.47× | ||
| Q1 25 | — | 1.33× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.29× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADPT
| Mrd Business Segment | $61.9M | 86% |
| Immune Medicine Business | $9.8M | 14% |
| Immune Medicine Service Revenue | $100.0K | 0% |
CWBC
Segment breakdown not available.
